All News

The federal agency has issued final guidance on how to design studies that include this patient population.

Questions remain surrounding the origin of the global pandemic.

Here are some news items in the urology field you may have missed this week.

Concepcion is editor-in-chief of Urology Times' sister publication, Urologists in Cancer Care.

Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of the agent.

The new treatment is a ready-to-use 6-month subcutaneous depot formulation of leuprolide mesylate.

The FDA has approved the PSMA PET imaging agent 18F-DCFPyL for use in prostate cancer.

The Uro-G single-use device arrives at a time when the FDA is actively investigating reports of infections associated with reusable cystoscopes.

Tadfin is a once-daily capsule that combines 5 mg of tadalafil (Cialis) with 5 mg of finasteride (Proscar).

The targeted focal laser ablation system is intended to be an office-based treatment for localized prostate cancer delivered under local anesthesia.

The SECURE trial is exploring the PSMA PET imaging product 64Cu-SAR-bisPSMA and the PSMA targeted therapy 67Cu-SAR-bisPSMA.

Final FDA decision on approvals is still pending.

The approval was based on data from the phase 3 ARCHES trial.

Around the Practice: High-Risk Renal Cell Carcinoma

Both medical professionals bring experience and expertise that will elevate the future work of the publication.

Ad Test

"I prefer doing transvaginal prolapse surgery with native tissue and always have. So I was not affected when mesh was restricted," says one urologist.

In this video, Gary Lemack, MD, offers a brief overview of overactive bladder treatments in development and explains their significance for providers and patients.

The benefits of holmium laser enucleation of the prostate with MOSES-enabled pulsed laser modulation justify its consideration as the gold standard surgical treatment for lower urinary tract symptoms related to benign prostatic hyperplasia, according to Amy E. Krambeck, MD.